A Phase 1, Open-label, Parallel-group Study to Evaluate the Effect of Moderate Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Bexagliflozin
Phase of Trial: Phase I
Latest Information Update: 01 Feb 2019
Price : $35 *
At a glance
- Drugs Bexagliflozin (Primary)
- Indications Hypertension; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Theracos
- 24 Jan 2019 Status changed from active, no longer recruiting to completed.
- 17 Dec 2018 Status changed from recruiting to active, no longer recruiting.
- 22 Aug 2018 Status changed from not yet recruiting to recruiting.